Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation
J Am Acad Dermatol
.
2024 Feb;90(2):408-410.
doi: 10.1016/j.jaad.2023.09.078.
Epub 2023 Oct 10.
Authors
Madison Hackley
1
,
Daphne Thampy
1
,
Shayan Waseh
1
,
Steven R Feldman
2
,
Andrew Blauvelt
3
,
Jeffrey M Weinberg
4
,
Sergio Schwartzman
5
,
Wilson Liao
6
,
Ronald Prussick
7
,
Jeffrey M Cohen
8
,
Sylvia Hsu
9
;
National Psoriasis Foundation Medical Board
Collaborators
National Psoriasis Foundation Medical Board
:
Dafna D Gladman
,
Soumya Reddy
,
Joseph Merola
,
Cassandra Calabrese
,
Mark Lebwohl
,
Chesahna Kindred
,
Lauren Miller
,
Leon Kircik
,
Clive Liu
,
G Michael Lewitt
,
Lara Wine Lee
,
Seemal Desai
,
Abby Van Voorhees
,
Brad P Glick
,
Jennifer Soung
Affiliations
1
Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
2
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
3
Oregon Medical Research Center, Portland, Oregon.
4
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
5
Hospital for Special Surgery, New York Prsebyterian Hospital, Weill Cornell Medical Center, New York, New York.
6
Department of Dermatology, University of California San Francisco, San Francisco, California.
7
Department of Dermatology, George Washington University, Washington, DC.
8
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
9
Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania. Electronic address:
[email protected]
.
PMID:
37821053
DOI:
10.1016/j.jaad.2023.09.078
No abstract available
MeSH terms
Acute Disease
Antibodies, Monoclonal, Humanized
Chronic Disease
Humans
Psoriasis* / diagnosis
Psoriasis* / etiology
Tuberculosis*
Substances
spesolimab
Antibodies, Monoclonal, Humanized